Dyadic is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives. The company's stock was previously traded OTC but is now traded on an exchange.
$1.51 -0.21 (-12.21%)
As of 02/07/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.